Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode for the week ended 3 July.

On the agenda this time are coronavirus vaccines, progress in NASH, the pricing of a new epilepsy drug and one multinational's efforts to assure investors of R&D progress.

Stories mentioned in this episode:

(Also see "Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine" - Scrip, 30 Jun, 2020.) 

(Also see "CanSino Coronavirus Vaccine Approved For Military Use In China" - Scrip, 29 Jun, 2020.)

(Also see "Intercept’s CRL Just Continues Upheaval In NASH" - Scrip, 29 Jun, 2020.)

(Also see "Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price" - Scrip, 28 Jun, 2020.)

(Also see "No Looking Back For Sanofi In R&D Turnaround Quest" - Scrip, 26 Jun, 2020.)

 

Related Content

Topics

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel